Investigating how well a COVID-19 vaccine works in people with HIV
SARS-CoV-2 vaccine durability during SIV infection
This study is looking at how well a new COVID-19 vaccine works for people living with HIV, especially those with weakened immune systems, to see if it can help them build strong protection against the virus.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10894621 on NIH RePORTER |
What this research studies
This research focuses on understanding the durability and effectiveness of a COVID-19 vaccine in individuals who are infected with HIV, particularly those who are immunosuppressed or untreated. The study uses a novel vaccine candidate that has shown promise in preclinical models, aiming to generate strong immunity against COVID-19 in these vulnerable populations. By utilizing advanced delivery methods, the research seeks to improve vaccine responses in patients who typically have weaker immune systems. The findings could help inform vaccination strategies in regions with high HIV prevalence.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living with HIV, particularly those who are immunosuppressed or have untreated infections.
Not a fit: Patients who are not living with HIV or those who are fully immunocompetent may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective COVID-19 vaccination strategies for individuals living with HIV, enhancing their protection against the virus.
How similar studies have performed: Other research has shown promise in using innovative vaccine platforms for immunocompromised populations, suggesting potential success for this approach.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: O'connor, Megan a — University of Washington
- Study coordinator: O'connor, Megan a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.